The DEL-1/β3 integrin axis promotes regulatory T cell responses during inflammation resolution
Xiaofei Li,Alessandra Colamatteo,Lydia Kalafati,Tetsuhiro Kajikawa,Hui Wang,Jong-Hyung Lim,Khalil Bdeir,Kyoung-Jin Chung,Xiang Yu,Clorinda Fusco,Antonio Porcellini,Salvatore De Simone,Giuseppe Matarese,Triantafyllos Chavakis,Veronica De Rosa,George Hajishengallis
DOI: https://doi.org/10.1172/jci137530
IF: 19.456
2020-10-26
Journal of Clinical Investigation
Abstract:FOXP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells (Tregs) are critical for immune homeostasis and respond to local tissue cues, which control their stability and function. We explored here whether developmental endothelial locus-1 (DEL-1), which, like Tregs, increases during resolution of inflammation, promotes Treg responses. DEL-1 enhanced Treg numbers and function at barrier sites (oral and lung mucosa). The underlying mechanism was dissected using mice lacking DEL-1 or expressing a point mutant thereof, or mice with T cell–specific deletion of the transcription factor RUNX1, identified by RNA sequencing analysis of the DEL-1–induced Treg transcriptome. Specifically, through interaction with αvβ3 integrin, DEL-1 promoted induction of RUNX1-dependent FOXP3 expression and conferred stability of FOXP3 expression upon Treg restimulation in the absence of exogenous TGF-β1. Consistently, DEL-1 enhanced the demethylation of the Treg-specific demethylated region (TSDR) in the mouse <i>Foxp3</i> gene and the suppressive function of sorted induced Tregs. Similarly, DEL-1 increased RUNX1 and FOXP3 expression in human conventional T cells, promoting their conversion into induced Tregs with increased TSDR demethylation, enhanced stability, and suppressive activity. We thus uncovered a DEL-1/αvβ3/RUNX1 axis that promotes Treg responses at barrier sites and offers therapeutic options for modulating inflammatory/autoimmune disorders.
medicine, research & experimental